A Phase I Study Evaluating the Feasibility and Safety of Infusion of "Re-Stimulated" Autologous Tumour-Infiltrating Lymphocytes (TILs) Followed by Low-Dose Interleukin-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a phase I clinical study for patients with platinum resistant (does not respond to
platinum-based chemotherapy) high grade serous ovarian, fallopian tube, or primary
peritoneal cancer. Prior to the main treatment, patients will receive cyclophosphamide by
vein. Patients will then receive an infusion (given by vein) of autologous
tumour-infiltrating lymphocytes (TILs) which will first be taken from the patient, then be
stimulated with certain substances called autologous dendritic cells (DCs) and OKT3
(anti-CD3 antibody), and then given back to the patient as an infusion. This is believed to
make the TILs work better. TILs are a type of white blood cells that recognizes tumour cells
and enter them which causes the tumour cells to break down. After infusion of TILs, low-dose
interleukin-2 (IL-2) therapy will be given.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society